IP Law 360

DECEMBER 4, 2023

biotech company Seagen Inc. will look to revive its claims seeking billions of dollars in damages in a dispute with Japanese drugmaker Daiichi Sankyo Co. over cancer drug patents, arguing that an arbitrator disregarded the "language and essence" of an underlying collaboration agreement.

Patent 52

Patent 52

Bio Law Blog

NOVEMBER 22, 2021

10, 2021, the Northern District of California granted the United States Patent and Trademark Office’s (USPTO) motion to dismiss a lawsuit brought by Apple and co-plaintiffs challenging the Patent Trial and Appeal Board’s (PTAB) use of the Fintiv factors in deciding whether to institute inter partes review (IPR). Andrei Iancu , No.

Litigation 52

Litigation Technology Patent Infringement Patent 52

SpicyIP

FEBRUARY 5, 2023

Book Release: ‘Archives, Ethics and the Law in India’ – A Guidebook for Archivists in India We announced the release of ‘Archives, Ethics and the Law in India’, an open-access publication co-authored by Farah Yameen and our blogger Divij Joshi. The guidebook is published by National Centre for Biological Sciences in Bangalore. 11 th Nov.

Music 119

Music Copyright Trademark IP 119

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Stimufend ® (Fresenius Kabi). Neulasta ® (Amgen). pegfilgrastim.

Litigation 52

Litigation Settlement Patent Marketing 52